Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Epidemiology and Surveillance

Surveillance and Molecular Epidemiology of Klebsiella pneumoniae Isolates That Produce Carbapenemases: First Report of OXA-48-Like Enzymes in North America

Christine Lascols, Gisele Peirano, Meredith Hackel, Kevin B. Laupland, Johann D. D. Pitout
Christine Lascols
aInternational Health Management Associates Inc., Schaumburg, Illinois, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gisele Peirano
bDivision of Microbiology, Calgary Laboratory Services, University of Calgary, Calgary, Alberta, Canada
cDepartments of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meredith Hackel
aInternational Health Management Associates Inc., Schaumburg, Illinois, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin B. Laupland
bDivision of Microbiology, Calgary Laboratory Services, University of Calgary, Calgary, Alberta, Canada
cDepartments of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
eMedicine, University of Calgary, Calgary, Alberta, Canada
fCritical Care Medicine, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johann D. D. Pitout
bDivision of Microbiology, Calgary Laboratory Services, University of Calgary, Calgary, Alberta, Canada
cDepartments of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
dMicrobiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01686-12
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A study was designed to characterize nonrepeat isolates of carbapenemase-producing K. pneumoniae obtained from the SMART worldwide surveillance program during 2008 and 2009. Characterization was done by PCR and sequencing for blaVIM, blaIMP, blaNDM, blaOXA, blaKPC, and plasmid-mediated quinolone resistance and virulence factors (VFs). Genetic relatedness was determined with pulsed-field gel electrophoresis (PFGE) using XbaI and multilocus sequence typing. A total of 110 isolates were included; 47 possess genes that encode K. pneumoniae carbapenemases (KPCs), 26 NDMs, 19 VIMs, 13 OXA-48-like, and 5 imipenems (IMPs). We identified 3 different major sequence types (STs) among 65% of the isolates (i.e., ST11 [n = 11], ST147 [n = 23], and ST258 [n = 38]). ST11 and ST147, producing OXA-48-like and NDMs, were found in Argentina, Turkey, Greece, Italy, and India; ST258, producing KPCs, was present in the United States, Israel, Greece, and Puerto Rico. The major STs consisted of up to 4 different pulsotypes, and each pulsotype had a specific geographical distribution. A new ST, named ST903, with blaIMP-26, was identified in the Philippines, while two blaOXA-48-positive isolates were detected in the United States. There were no significant differences in the distribution of the VFs between the isolates; all were positive for fimH, mrkD, wabG, and ureA. This is the first report of OXA-48-like enzymes in North America. Our study highlights the importance of surveillance programs using molecular techniques as powerful tools to identify the importance of international sequence types.

INTRODUCTION

The Enterobacteriaceae, most notably Escherichia coli and Klebsiella pneumoniae, are among the most important causes of serious hospital-acquired and community onset bacterial infections in humans (1). Since β-lactam antibiotics are a major drug class used to treat serious community onset or hospital-acquired infections caused by Enterobacteriaceae, resistance to these agents will continue to challenge clinical therapeutic choices. Of special concern is the development of resistance to the carbapenems, since these agents are often the last line of effective therapy available for the treatment of infections caused by multiresistant Enterobacteriaceae (2).

Most important within the Enterobacteriaceae is the increasing recognition of isolates that produce carbapenemases, which cause resistance to the carbapenems. They include the class A (K. pneumoniae carbapenemase [KPC] types), the class B (metallo-β-lactamases [MBLs] [i.e., VIM, imipenem {IPM}, and NDM types]), and the class D (e.g., OXA-48-like enzymes) oxacillinases (3).

Multilocus sequence typing (MLST), which uses sequence variation in a number of housekeeping genes to define sequence types (STs), or clones, is an excellent tool for evolutionary studies to show common-ancestry lineages among bacteria (4). It has led to the definition of major sequence types and the recognition of successful widespread international antimicrobial-resistant sequence types, such as E. coli ST101, which produces NDMs (5); E. coli ST131, which produces various extended-spectrum β-lactamases (ESBLs) (6); and K. pneumoniae ST258, which produces KPCs (7).

Several worldwide surveillance studies have shown the emergence of Enterobacteriaceae that produce carbapenemases, especially KPCs in the United States and NDMs in the Indian subcontinent (8–10). However, limited information is available about the molecular epidemiology of carbapenamase-producing Enterobacteriaceae from different parts of the world. A study was designed to characterize nonrepeat isolates of carbapenemase-producing K. pneumoniae obtained from the SMART worldwide surveillance program during 2008 and 2009.

MATERIALS AND METHODS

Bacterial isolates.One hundred and ten nonduplicate isolates of K. pneumoniae from intra-abdominal infections collected as part of the SMART surveillance program during 2008 and 2009 were included in this study (11). Isolates were obtained from Europe (20 sites), Asia (27 sites), North America (20 sites), Latin America (12 sites), the South Pacific (6 sites), and the Middle East (2 sites).

Antimicrobial susceptibility testing.MICs of ampicillin-sulbactam (SAM), piperacillin-tazobactam (TZP), cefoxitin (FOX), cefotaxime (CTX), ceftriaxone (CRO), ceftazidime (CAZ), cefepime (FEP), ertapenem (ERT), IPM, amikacin (AMK), ciprofloxacin (CIP), tigecycline (TIG), and colistin (COL) were determined using dehydrated broth microdilution MicroScan panels (Siemens Healthcare Diagnostics, IL) or in-house panels (COL) following 2012 CLSI and manufacturers' guidelines (12). Throughout this study, results were interpreted using 2012 CLSI breakpoints for broth dilution (12). The European Committee for Antimicrobial Susceptibility Testing (EUCAST) breakpoint was used for COL, and the FDA breakpoint was used for TIG.

β-Lactamase gene identification.KPC, OXA-48-like, VIM, IMP, and NDM-carbapenemases were identified using PCR amplification and sequencing as described previously (10). A microarray assay (Check-MDR CT101; Check-Points, The Netherlands) was also used to detect additional β-lactamases, as described previously (10).

Plasmid-mediated quinolone resistance (PMQR) determinants.The amplification of the qnrA, qnrS, and qnrB genes was undertaken in all isolates with multiplex PCR (13). aac(6′)-lb and qepA were amplified in separate PCRs using primers and conditions previously described (14, 15). The variant aac(6′)-lb-cr was further identified by digestion with BstF5I (New England BioLabs, Ipswich, MA).

16S rRNA methylation.The amplification of genes encoding 16 RNA methylases was determined using a multiplex PCR described by Doi and Arakawa (16).

Virulence factors in K. pneumoniae.PCR as described by Brisse et al. was used to determine the presence of virulence genes that have previously been associated with virulence in K. pneumoniae (17). They included the following: uge (encoding UDP galacturonate 4-epimerase), wabG (involved in the biosynthesis of the outer core lipopolysaccharide), ureA (related to the urease operon), magA (mucoviscosity-associated gene A), mrkD (type 3 fimbrial adhesion), allS (activator of the allantoin regulon), kfuBC (iron uptake system), rpmA (regulator of mucoid phenotype), and fimH (fimbrial gene encoding type 1 fimbrial adhesion).

PFGE.The genetic relatedness of the ESBL-producing K. pneumoniae isolates was examined by pulsed-field gel electrophoresis (PFGE) following the extraction of genomic DNA and digestion with XbaI using the standardized E. coli (O157:H7) protocol established by the Centers for Disease Control and Prevention, Atlanta, GA (18). The subsequent PFGE analyses were performed on a Chef Mapper apparatus (Bio-Rad Laboratories, Hercules, CA). PFGE banding patterns were analyzed with BioNumerics software (Applied Maths, Kortrijk, Belgium), and the relatedness was calculated by the unweighted-pair group method using average linkages (UPGMA) algorithm, with similarity of bands calculated using the Dice coefficient. Cluster designation was based on the criteria of Tenover et al. (19).

MLST.MLST was performed using seven conserved housekeeping genes (gapA, infB, mdh, pgi, phoE, rpoB, and tonB) (20). A detailed protocol of the MLST procedure, including allelic type and ST assignment methods, is available in MLST databases from the Pasteur Institute, Paris, France (http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html). New alleles and STs were submitted to the MLST website and were approved. The eBURST V3 algorithm (http://eburst.mlst.net/) was used to demonstrate phylogenetic relationships among closely related STs. Those STs that differed from the ancestor at one of the seven MLST alleles were defined as single-locus variants (SLVs), while STs that differed at two of the seven MLST alleles were defined as double-locus variants (DLVs). Clonal complexes (CCs) were defined as groups of STs that are related to each other by SLV level. For the purpose of this study, we included major sequence types only if 10 or more isolates belonged to that specific sequence type.

Statistical methods.Data were analyzed using Stata 11.2 (StataCorp, College Station, TX). Fishers' exact and χ2 tests were used for comparing categorical variables among two and multiple groups, respectively. P values of less than 0.05 were deemed to represent statistical significance.

Nucleotide sequence accession number.The sequence of VIM-33 was submitted to GenBank under accession number JX258134.

RESULTS

Bacterial isolates, β-lactamases, susceptibilities, PMQR, and RNA methylases.A total of 110 K. pneumoniae isolates that produce carbapenemases were included in this study: 47 that produce KPCs (i.e., KPC-2 [n = 23], KPC-3 [n = 18], and KPC-11 [n = 6]), 26 that produce NDM-1, 19 that produce VIMs (i.e., VIM-1 [n = 16], VIM-5 [n = 1], VIM-27 [n = 1], and VIM-33 [n = 1]), 13 that produce OXA-48-like (i.e., OXA-48 [n = 6], OXA-163 [n = 2], and OXA-181 [n = 5]), and 5 that produce IMP-26 (Table 1). Some of the isolates also produced ESBLs (SHV-2, -5, -12, and -31; CTX-M-3, -14 and -15) and plasmid-mediated AmpC β-lactamases (CMY-2 and DHA-1) (Table 2 shows details).

View this table:
  • View inline
  • View popup
Table 1

Numbers of K. pneumoniae isolates that produce different carbapenemasesa

View this table:
  • View inline
  • View popup
Table 2

Sequence types of Klebsiella pneumoniae that produce carbapenemases

All the isolates included in this study were nonsusceptible (NS) (i.e., either intermediate or resistant) to SAM, FOX, CTX, CRO, ERT, IPM, or CIP, and 97% were NS to TZP and FEP, 95% to AMK, 32% to COL, and 15% to TIG.

Eight (7%) of the K. pneumoniae isolates that produced carbapenemases were positive for aac(6′)-lb-cr, 23 (21%) for aac(6′)-lb-cr with qnrB, 1 (1%) for aac(6′)-lb-cr with qnrS, 5 (5%) for qnrB, 4 (4%) for qnrA, and 1 (1%) for qnrS (Table 3). All the isolates were negative for qepA.

View this table:
  • View inline
  • View popup
Table 3

Characteristics of K. pneumoniae sequence types ST11, ST147, and ST258 and other STs that produce carbapenemases

Twenty (18%) of the K. pneumoniae isolates that produced carbapenemases were positive for armA, 2 (2%) for armA with rmtB, 5 (5%) for rmtC, and 2 (2%) for rmtB (Table 3).

Virulence factors.All 110 isolates tested positive for fimH, wabG, and urea; 108 (98%) were positive for mrkD, 105 (95%) for uge, 11 (10%) for kfuB, and 7 (6%) for alls. All the isolates were negative for magA, rpmA, and aerobactin (Table 3).

Pulsed-field gel electrophoresis.PFGE identified 3 major clusters (with more than 10 isolates per cluster) of K. pneumoniae among 72 isolates, which were designated clusters A (n = 11), B (n = 23), and C (n = 38). Ten minor clusters (with less than 10 isolates per cluster) were also identified: clusters D (n = 2), E (n = 2), F (n = 2), G (n = 4), H (n = 2), I (n = 2), J (n = 3), K (n = 2), L (n = 4), and M (n = 2). The isolates that belonged to clusters A to M had >80% similar PFGE profiles among the isolates of each cluster. Interestingly, isolates that belonged to clusters A, H, I, and L exhibited >60% similarity of PFGE profiles to cluster C, and this suggested that they were related to cluster C. The remaining isolates (n = 13) were not clonally related, i.e., exhibited <60% similar PFGE profiles and did not show patterns similar to those from clusters A to M.

MLST.MLST identified the “major” clusters as follows: cluster A, ST11; B, ST147; and C, ST258. The “minor” clusters belonged to the following sequence types: cluster D, ST1; E, ST14; F, ST15; G, ST17; H, ST340; I, ST418; J, ST43; K, ST478; L, ST512; and M, ST626. ST11, ST340, ST418, and ST512 are SLVs of ST258 and explained the similarity of PFGE patterns between these sequence types. The remaining 13 isolates were identified as ST101, ST20, ST231, ST271, ST278, ST29, ST336, ST34, ST391, ST437, ST572, ST676, and ST903 (Table 2). ST903, isolated in the Philippines, was described for the first time in this study with a novel allele (i.e., phoE151). ST903, with blaIMP-26, was positive for armA, rmtB, and qnrB. The eBURST analysis of ST903 showed that it is not associated with any clonal complex.

ST11 and ST258 each consisted of 4 different pulsotypes, and ST147 consisted of 3 pulsotypes (i.e., there were >90% similar PFGE profiles among the isolates of each pulsotype). The geographical distribution and the presence of ESBL and AmpC β-lactamases of the different major sequence types ST11, ST147, and ST258, with their respective pulsotypes, are shown in Table 2. It was interesting that the isolates within each pulsotype produced similar carbapenemases and ESBLs and had the same geographical distribution (e.g., isolates that belonged to pulsotype 147A produced NDM-1 with CTX-M-15 and were present in India, while isolates that belonged to pulsotype 147D produced VIMs with SHV-12 and were mostly present in Greece).

ST11 produced NDM-1, OXA-48-like, and CTX-M-15; was present in India, Argentina, and Turkey; and was often positive for aac(6′)-lb-cr (Table 3). ST147 mostly produced VIMs, NDM-1, and CTX-M-15; was present in India, Greece, and Italy; and was often positive for aac(6′)-lb-cr with qnrB and armA (Table 3). ST258 produced KPC and SHV-12; was present in Greece, the United States, Israel, and Puerto Rico (1 isolate); and was not associated with PMQR determinants or 16S RNA methylases (Table 3). There were no significant differences in the presence of virulence factors between ST11, ST147, ST258, and the other sequence types (Table 3). Over half of ST258 isolates (53%) were NS to COL, while 35% of ST147 isolates were NS to TIG.

Some interesting geographical distributions were also noted among the minor sequence types. ST1 with VIM-1 was present in Spain; ST14 with KPC-2, VIM-1, and OXA-48 in Greece and Turkey; ST43 with OXA-181 and VIM-5 in India and Turkey; ST478 with IMP-26 in Australia; and ST512 with KPC-2 in Israel and Columbia (Table 2).

DISCUSSION

The pandemics caused by CTX-M-, KPC-, and NDM-producing Enterobacteriaceae between 2000 and 2010 highlighted the desperate need for global antimicrobial resistance surveillance systems, especially in resource-limited countries, where novel resistance mechanisms are more likely to emerge (21). These surveillance systems would help to determine the scope of antimicrobial resistance in resource-limited countries, while molecular characterization would ensure the early recognition of novel resistance mechanisms, including the worldwide emergence of certain successful international clones or sequence types (21). Studies that combine surveillance with molecular characterization would also help with the development of rapid techniques to detect novel or emerging resistance mechanisms in travelers returning from areas of endemicity. This would ensure the appropriate implementation of infection control measures and help to curb the worldwide spread of antibiotic resistance.

The SMART program is one of the few worldwide surveillance systems that has a wide representation of microbiology laboratories among resource-limited countries. The program started in 2002 to monitor antimicrobial resistance trends among isolates from intra-abdominal-infection isolates obtained from Asia, Latin America, the South Pacific, and the Middle East. The molecular characterization of the SMART isolates started in 2008. We believe this surveillance program provides a unique opportunity to study the significance and importance of certain sequence types with their respective pulsotypes among K. pneumoniae that produce carbapenemases.

Infections with KPC-, VIM-, OXA-48-like-, and NDM-producing Enterobacteriaceae have most often been associated with visiting and being hospitalized in areas of endemicity, such as the United States, Greece, and Israel for KPCs; Greece for VIMs; Turkey for OXA-48-like; and the Indian subcontinent for NDMs (21). The results from our study support this notion (Table 1); KPC-producing isolates were mostly found in Greece, the United States, and Israel; NDM-1 producers in India; VIM producers in Greece; and IMP producers in Australia and the Philippines, while K. pneumoniae with OXA-48-like β-lactamases were present in India (OXA-181), Turkey (OXA-48), Argentina (OXA-163), and, surprisingly, the United States. To our knowledge, this is the first description of OXA-48-like β-lactamases from the North American continent. The 2 isolates from the United States were obtained during 2009; produced OXA-48 and CTX-M-15; belonged to ST15 and ST336, respectively; and were positive for aac(6′)-lb-cr with qnrB.

KPC-producing bacteria are endemic in certain parts of the world, and intercontinental dissemination of ST258 has contributed to the worldwide spread of KPC-producing K. pneumoniae (7). Of the 47 KPC-producing isolates included in our study, 38 (81%) belonged to ST258, which consisted of 4 different pulsotypes; pulsotypes 258A and 258B with KPC-3 were found in the United States and Israel, pulsotype 258C with KPC-2 and -11 was limited to Greece, while pulsotype 258D with KPC-2 was present in the United States and Puerto Rico (Table 2). A highly epidemic clone of KPC-3-producing K. pneumoniae emerged in Israel during 2006, causing several nosocomial outbreaks with high mortality among patients, and was most likely introduced into Israel via travelers from the United States during the early to middle part of 2000 to 2010 (22). The fact that pulsotypes 258A and 258B with KPC-3 were present in the United States and Israel (but absent in KPC isolates from Greece) suggests that there is still intercountry transfer of patients colonized or infected with KPC-3-producing K. pneumoniae. In 2008, 32 patients presented with infections due to KPC-producing K. pneumoniae in a Columbian hospital; the index case was a medical tourist who traveled from Israel to undergo a liver transplantation (23). We identified ST512, an SLV of ST258, in isolates from Israel and Columbia (Table 2), again supporting the notion that KPC-producing K. pneumoniae can travel with travelers and can easily be introduced into a country or region.

K. pneumoniae isolates that produce VIMs were first reported during 2002 from patients admitted to intensive care units (ICUs) of three teaching hospitals located in Athens, Greece (24). K. pneumoniae with VIM-1 is endemic in certain hospitals in Greece, and nosocomial infections caused by these bacteria constitute a major public health problem for the Mediterranean country (25). VIM-27, a single-point variant of VIM-1, has been described in K. pneumoniae ST147 recovered from hospitals in Greece (26). Of the 19 VIM-producing isolates included in our study, 12 (63%) belonged to ST147, which consisted of 3 different pulsotypes: pulsotypes 147A with NDM-1 and 147B with OXA-181 were found in India, while pulsotype 147C with VIM-1, -27, and -33 was limited to Greece and Italy (Table 2). VIM-33, first described in this study, is a point mutant variant of VIM-1 and was present in Greece. Interestingly, the 2 VIM-1-producing isolates from Spain belonged to a different sequence type, namely, ST1.

The majority of the patients from North America, Europe, and Australia infected with NDM-producing bacteria were previously hospitalized in the Indian subcontinent (27). All the NDM-1-producing K. pneumoniae isolates (n = 26) from this study were isolated from sites in India; interestingly, 9 (35%) belonged to ST147 and 6 (23%) to ST11 (i.e., over 50% of NDM-producing K. pneumoniae isolates from India belonged to either ST11 or ST147). It is therefore possible that clonal spread of NDM-1 among K. pneumoniae isolates in India could be more significant than previously believed.

We identified 3 different major sequence types, namely, ST11, ST147, and ST258, among the majority of isolates (65%) identified during 2008 and 2009. ST11 is a truly international sequence type and has been associated with NDMs (28, 29), KPC (30–32), and CTX-M-15 (33). Our results show that this sequence type also has the ability to produce OXA-48-like enzymes from isolates found in Argentina and Turkey (Table 3). ST147 has only recently been described in Greece (26) and has been associated with VIMs and KPCs in that country (34). This sequence type is also associated with NDMs from Canada (35) and the United Kingdom (28) and VIMs from Scandinavia (36). ST147 in our study was associated with VIMs, NDMs, and OXA-48-like enzymes from K. pneumoniae isolates in India, Greece, and Italy (Table 3). These sequence types, especially ST147 and ST258, pose important new public health threats in countries such as the United States, Israel, Greece, and India. Our results also show that these major sequence types are possibly being imported into countries such as Puerto Rico, Columbia, Italy, and Argentina.

A study by Johnson and colleagues investigating a different successful international sequence type, E. coli ST131, showed that the unique combination of antimicrobial resistance and certain virulence factors most likely give ST131 a competitive advantage over other isolates of E. coli, promoting its clonal expansion and dominance over less virulent and/or more susceptible E. coli clones (37). We investigated the susceptibilities and virulence factors of ST11, ST147, and ST258 and compared the results to those for other sequence types identified in this study (Table 3). ST258 was significantly more resistant to colistin, but we failed to identify certain virulence factors that might have been responsible for the international success of ST258 (Table 3).

ST11, ST147, and ST258 are major drug-resistant pathogens among K. pneumoniae strains that produce carbapenemases in different parts of the world. We urgently need well-designed epidemiological and molecular studies to understand the dynamics of transmission, risk factors, and reservoirs for K. pneumoniae ST11, ST147, and ST258. This will provide insight into the emergence and spread of these multiresistant sequence types that will hopefully lead to information essential for preventing infections and the spread of these bacteria.

ACKNOWLEDGMENTS

J.D.D.P. and K.B.L. previously received research funds from Merck, Pfizer, and Astra Zeneca.

This work was supported by a research grant from Calgary Laboratory Services (number 73-6350).

FOOTNOTES

    • Received 14 August 2012.
    • Returned for modification 7 October 2012.
    • Accepted 9 October 2012.
    • Accepted manuscript posted online 15 October 2012.
  • Copyright © 2013, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Paterson DL
    . 2006. Resistance in gram-negative bacteria: Enterobacteriaceae. Am. J. Infect. Control 34:S20–S28, S64–S73.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Livermore DM,
    2. Woodford N
    . 2006. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14:413–420.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Kalpoe JS,
    2. Al Naiemi N,
    3. Poirel L,
    4. Nordmann P
    . 2011. Detection of an Ambler class D OXA-48-type beta-lactamase in a Klebsiella pneumoniae strain in The Netherlands. J. Med. Microbiol. 60:677–678.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Sullivan CB,
    2. Diggle MA,
    3. Clarke SC
    . 2005. Multilocus sequence typing: data analysis in clinical microbiology and public health. Mol. Biotechnol. 29:245–254.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Mushtaq S,
    2. Irfan S,
    3. Sarma JB,
    4. Doumith M,
    5. Pike R,
    6. Pitout J,
    7. Livermore DM,
    8. Woodford N
    . 2011. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J. Antimicrob. Chemother. 66:2002–2005.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Peirano G,
    2. Pitout JD
    . 2010. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int. J. Antimicrob. Agents 35:316–321.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Nordmann P,
    2. Cuzon G,
    3. Naas T
    . 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228–236.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Castanheira M,
    2. Deshpande LM,
    3. Mathai D,
    4. Bell JM,
    5. Jones RN,
    6. Mendes RE
    . 2011. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006–2007. Antimicrob. Agents Chemother. 55:1274–1278.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Castanheira M,
    2. Mendes RE,
    3. Woosley LN,
    4. Jones RN
    . 2011. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007–09). J. Antimicrob. Chemother. 66:1409–1411.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Lascols C,
    2. Hackel M,
    3. Marshall SH,
    4. Hujer AM,
    5. Bouchillon S,
    6. Badal R,
    7. Hoban D,
    8. Bonomo RA
    . 2011. Increasing prevalence and dissemination of NDM-1 metallo-beta-lactamase in India: data from the SMART study (2009). J. Antimicrob. Chemother. 66:1992–1997.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Hawser SP,
    2. Bouchillon SK,
    3. Lascols C,
    4. Hackel M,
    5. Hoban DJ,
    6. Badal RE,
    7. Woodford N,
    8. Livermore DM
    . 2011. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob. Agents Chemother. 55:3917–3921.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. M100-S22. CLSI, Wayne, PA.
  13. 13.↵
    1. Robicsek A,
    2. Strahilevitz J,
    3. Sahm DF,
    4. Jacoby GA,
    5. Hooper DC
    . 2006. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob. Agents Chemother. 50:2872–2874.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Park CH,
    2. Robicsek A,
    3. Jacoby GA,
    4. Sahm D,
    5. Hooper DC
    . 2006. Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob. Agents Chemother. 50:3953–3955.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Yamane K,
    2. Wachino J,
    3. Suzuki S,
    4. Arakawa Y
    . 2008. Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. Antimicrob. Agents Chemother. 52:1564–1566.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Doi Y,
    2. Arakawa Y
    . 2007. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis. 45:88–94.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Brisse S,
    2. Fevre C,
    3. Passet V,
    4. Issenhuth-Jeanjean S,
    5. Tournebize R,
    6. Diancourt L,
    7. Grimont P
    . 2009. Virulent clones of Klebsiella pneumoniae: identification and evolutionary scenario based on genomic and phenotypic characterization. PLoS One 4:e4982. doi:10.1371/journal.pone.0004982.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hunter SB,
    2. Vauterin P,
    3. Lambert-Fair MA,
    4. Van Duyne MS,
    5. Kubota K,
    6. Graves L,
    7. Wrigley D,
    8. Barrett T,
    9. Ribot E
    . 2005. Establishment of a universal size standard strain for use with the PulseNet standardized pulsed-field gel electrophoresis protocols: converting the national databases to the new size standard. J. Clin. Microbiol. 43:1045–1050.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Tenover FC,
    2. Arbeit RD,
    3. Goering RV,
    4. Mickelsen PA,
    5. Murray BE,
    6. Persing DH,
    7. Swaminathan B
    . 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233–2239.
    OpenUrlFREE Full Text
  20. 20.↵
    1. Diancourt L,
    2. Passet V,
    3. Verhoef J,
    4. Grimont PA,
    5. Brisse S
    . 2005. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J. Clin. Microbiol. 43:4178–4182.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Van der Bij AK,
    2. Pitout JD
    . 2012. The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. J. Antimicrob. Chemother. 67:2090–2100.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Navon-Venezia S,
    2. Leavitt A,
    3. Schwaber MJ,
    4. Rasheed JK,
    5. Srinivasan A,
    6. Patel JB,
    7. Carmeli Y
    . 2009. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob. Agents Chemother. 53:818–820.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Lopez JA,
    2. Correa A,
    3. Navon-Venezia S,
    4. Correa AL,
    5. Torres JA,
    6. Briceno DF,
    7. Montealegre MC,
    8. Quinn JP,
    9. Carmeli Y,
    10. Villegas MV
    . 2011. Intercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strain. Clin. Microbiol. Infect. 17:52–56.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Giakkoupi P,
    2. Xanthaki A,
    3. Kanelopoulou M,
    4. Vlahaki A,
    5. Miriagou V,
    6. Kontou S,
    7. Papafraggas E,
    8. Malamou-Lada H,
    9. Tzouvelekis LS,
    10. Legakis NJ,
    11. Vatopoulos AC
    . 2003. VIM-1 Metallo-beta-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J. Clin. Microbiol. 41:3893–3896.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Vatopoulos A
    . 2008. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece—a review of the current evidence. Euro Surveill. 13:pii:8023.
  26. 26.↵
    1. Papagiannitsis CC,
    2. Kotsakis SD,
    3. Petinaki E,
    4. Vatopoulos AC,
    5. Tzelepi E,
    6. Miriagou V,
    7. Tzouvelekis LS
    . 2011. Characterization of metallo-beta-lactamase VIM-27, an A57S mutant of VIM-1 associated with Klebsiella pneumoniae ST147. Antimicrob. Agents Chemother. 55:3570–3572.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Nordmann P,
    2. Poirel L,
    3. Walsh TR,
    4. Livermore DM
    . 2011. The emerging NDM carbapenemases. Trends Microbiol. 19:588–595.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Giske CG,
    2. Froding I,
    3. Hasan CM,
    4. Turlej-Rogacka A,
    5. Toleman M,
    6. Livermore D,
    7. Woodford N,
    8. Walsh TR
    . 2012. Diverse sequence types of Klebsiella pneumoniae contribute to the dissemination of blaNDM-1 in India, Sweden, and the United Kingdom. Antimicrob. Agents Chemother. 56:2735–2738.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Williamson DA,
    2. Sidjabat HE,
    3. Freeman JT,
    4. Roberts SA,
    5. Silvey A,
    6. Woodhouse R,
    7. Mowat E,
    8. Dyet K,
    9. Paterson DL,
    10. Blackmore T,
    11. Burns A,
    12. Heffernan H
    . 2012. Identification and molecular characterisation of New Delhi metallo-beta-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. Int. J. Antimicrob. Agents 39:529–533.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Balm MN,
    2. Ngan G,
    3. Jureen R,
    4. Lin RT,
    5. Teo J
    . 2012. Molecular characterization of newly emerged blaKPC-2-producing Klebsiella pneumoniae in Singapore. J. Clin. Microbiol. 50:475–476.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Baraniak A,
    2. Grabowska A,
    3. Izdebski R,
    4. Fiett J,
    5. Herda M,
    6. Bojarska K,
    7. Zabicka D,
    8. Kania-Pudlo M,
    9. Mlynarczyk G,
    10. Zak-Pulawska Z,
    11. Hryniewicz W,
    12. Gniadkowski M
    . 2011. Molecular characteristics of KPC-producing Enterobacteriaceae at the early stage of their dissemination in Poland, 2008–2009. Antimicrob. Agents Chemother. 55:5493–5499.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Qi Y,
    2. Wei Z,
    3. Ji S,
    4. Du X,
    5. Shen P,
    6. Yu Y
    . 2011. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. J. Antimicrob. Chemother. 66:307–312.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Damjanova I,
    2. Toth A,
    3. Paszti J,
    4. Hajbel-Vekony G,
    5. Jakab M,
    6. Berta J,
    7. Milch H,
    8. Fuzi M
    . 2008. Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type beta-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005—the new ‘MRSAs’? J. Antimicrob. Chemother. 62:978–985.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Giakkoupi P,
    2. Papagiannitsis CC,
    3. Miriagou V,
    4. Pappa O,
    5. Polemis M,
    6. Tryfinopoulou K,
    7. Tzouvelekis LS,
    8. Vatopoulos AC
    . 2011. An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009–10). J. Antimicrob. Chemother. 66:1510–1513.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Peirano G,
    2. Pillai DR,
    3. Pitondo-Silva A,
    4. Richardson D,
    5. Pitout JD
    . 2011. The characteristics of NDM-producing Klebsiella pneumoniae from Canada. Diagn. Microbiol. Infect. Dis. 71:106–109.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Samuelsen O,
    2. Toleman MA,
    3. Hasseltvedt V,
    4. Fuursted K,
    5. Leegaard TM,
    6. Walsh TR,
    7. Sundsfjord A,
    8. Giske CG
    . 2011. Molecular characterization of VIM-producing Klebsiella pneumoniae from Scandinavia reveals genetic relatedness with international clonal complexes encoding transferable multidrug resistance. Clin. Microbiol. Infect. 17:1811–1816.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Johnson JR,
    2. Johnston B,
    3. Clabots C,
    4. Kuskowski MA,
    5. Castanheira M
    . 2010. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 51:286–294.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Surveillance and Molecular Epidemiology of Klebsiella pneumoniae Isolates That Produce Carbapenemases: First Report of OXA-48-Like Enzymes in North America
Christine Lascols, Gisele Peirano, Meredith Hackel, Kevin B. Laupland, Johann D. D. Pitout
Antimicrobial Agents and Chemotherapy Dec 2012, 57 (1) 130-136; DOI: 10.1128/AAC.01686-12

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Surveillance and Molecular Epidemiology of Klebsiella pneumoniae Isolates That Produce Carbapenemases: First Report of OXA-48-Like Enzymes in North America
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Surveillance and Molecular Epidemiology of Klebsiella pneumoniae Isolates That Produce Carbapenemases: First Report of OXA-48-Like Enzymes in North America
Christine Lascols, Gisele Peirano, Meredith Hackel, Kevin B. Laupland, Johann D. D. Pitout
Antimicrobial Agents and Chemotherapy Dec 2012, 57 (1) 130-136; DOI: 10.1128/AAC.01686-12
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596